## Mikila R Jacobson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3794623/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Repetitive nasal allergen challenge in allergic rhinitis: Priming and Th2â€ŧype inflammation but no evidence of remodelling. Clinical and Experimental Allergy, 2021, 51, 329-338.	2.9	22
2	Severe Persistent Allergic Rhinitis. Inflammation but No Histologic Features of Structural Upper Airway Remodeling. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1431-1439.	5.6	36
3	Despite Inflammation, No Structural Upper Airway Remodelling In Severe Allergic Rhinitis. Journal of Allergy and Clinical Immunology, 2014, 133, AB145.	2.9	1
4	Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. Journal of Allergy and Clinical Immunology, 2011, 127, 509-516.e5.	2.9	299
5	Cochrane review: Allergen injection immunotherapy for seasonal allergic rhinitis. Evidence-Based Child Health: A Cochrane Review Journal, 2010, 5, 1279-1379.	2.0	3
6	Grass pollen immunotherapy induces Foxp3-expressing CD4+CD25+ cells in the nasal mucosa. Journal of Allergy and Clinical Immunology, 2008, 121, 1467-1472.e1.	2.9	285
7	Allergen injection immunotherapy for perennial allergic rhinitis. The Cochrane Library, 2008, , .	2.8	2
8	Grass Pollen Immunotherapy Induces an Allergen-Specific IgA2 Antibody Response Associated with Mucosal TGF-β Expression. Journal of Immunology, 2007, 178, 4658-4666.	0.8	216
9	Allergen injection immunotherapy for seasonal allergic rhinitis. The Cochrane Library, 2007, , CD001936.	2.8	385
10	ls occupational asthma to diisocyanates a non–IgE-mediated disease?. Journal of Allergy and Clinical Immunology, 2006, 117, 663-669.	2.9	73
11	Objective monitoring of nasal airway inflammation in rhinitis. Journal of Allergy and Clinical Immunology, 2005, 115, S414-S441.	2.9	123
12	IL-9 and c-Kit+ mast cells in allergic rhinitis during seasonal allergen exposure: Effect of immunotherapy. Journal of Allergy and Clinical Immunology, 2005, 116, 73-79.	2.9	99
13	CXCR1+CD4+T Cells in Human Allergic Disease. Journal of Immunology, 2004, 172, 268-273.	0.8	24
14	Grass Pollen Immunotherapy Induces Mucosal and Peripheral IL-10 Responses and Blocking IgG Activity. Journal of Immunology, 2004, 172, 3252-3259.	0.8	496
15	Inhibition of nasal mucosal eosinophils after immunotherapy is associated with a decrease in interleukin-13 mRNA and vascular cell adhesion molecule-1 expression. Allergology International, 2004, 53, 255-264.	3.3	1
16	Regulation of CCR4 expression after segmental bronchial allergen challenge in atopic asthmatics. Journal of Allergy and Clinical Immunology, 2002, 109, S41-S41.	2.9	1
17	Grass pollen immunotherapy (IT) increases IL-10- and TGF-β-mRNA expression in the nasal mucosa during the pollen season. Journal of Allergy and Clinical Immunology, 2002, 109, S171-S171.	2.9	3
18	CCR4 in human allergen-induced late responses in the skin and lung. European Journal of Immunology, 2002, 32, 1933.	2.9	60

Mikila R Jacobson

#	Article	IF	CITATIONS
19	Grass pollen immunotherapy: Symptomatic improvement correlates with reductions in eosinophils and IL-5 mRNA expression in the nasal mucosa during the pollen season. Journal of Allergy and Clinical Immunology, 2001, 107, 971-976.	2.9	115
20	Basophil recruitment and IL-4 production during human allergen-induced late asthma. Journal of Allergy and Clinical Immunology, 2001, 108, 205-211.	2.9	102
21	Increased expression of IL-16 immunoreactivity in bronchial mucosa after segmental allergen challenge in patients with asthma. Journal of Allergy and Clinical Immunology, 2000, 106, 293-301.	2.9	49
22	Long-Term Clinical Efficacy of Grass-Pollen Immunotherapy. New England Journal of Medicine, 1999, 341, 468-475.	27.0	1,256
23	Expression of IL-4, Cl̈µ RNA, and Il̈µ RNA in the nasal mucosa of patients with seasonal rhinitis: Effect of topical corticosteroids⠆⠆⠆â îâ Journal of Allergy and Clinical Immunology, 1998, 101, 330-336.	2.9	79
24	IL-13 mRNA and Immunoreactivity in Allergen-induced Rhinitis: Comparison with IL-4 Expression and Modulation by Topical Glucocorticoid Therapy. American Journal of Respiratory Cell and Molecular Biology, 1997, 17, 17-24.	2.9	77
25	Expression of IL-16 in allergen-induced late-phase nasal responses and relation to topical glucocorticosteroid treatment. Journal of Allergy and Clinical Immunology, 1997, 100, 569-574.	2.9	43
26	Expression of É> germ-line gene transcripts and mRNA for the É> heavy chain of IgE in nasal B cells and the effects of topical corticosteroid. European Journal of Immunology, 1997, 27, 2899-2906.	2.9	163
27	Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon- <sup>î3</sup> . Journal of Allergy and Clinical Immunology, 1996, 97, 1356-1365.	2.9	383
28	Kinetics of cell infiltration and cytokine messenger RNA expression after intradermal challenge with allergen and tuberculin in the same atopic individuals. Journal of Allergy and Clinical Immunology, 1994, 94, 764-772.	2.9	91